We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brazilian media sources report that a group of unidentified local drug firms has promised health officials a cheap copy of US-based Abbott Laboratories' ARV Kaletra, in the event that the government decides to compulsorily license the drug.
After months of flat growth, Germany's drug market is reported to be expanding solidly again. However, local health funds now warn that expenditure could rise at an unsustainable rate this year.
Following the introduction of WHO-compliant patent legislation in India, the country's round-table Working Group on Patent Laws has asked the government to protect the domestic drug industry and ensure continued supplies of affordable medicines.
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that it has exercised an option for a license from Wake Forest University Health Sciences and Cedars Sinai Medical Center to three patents encompassing triple hormone contraception technology, a novel combination of estrogens and progestins with androgens, such as testosterone.
German drug-maker Bayer AG nearly tripled its second-quarter profit on strong sales in its health-care and chemical businesses, but it still missed expectations and its shares fell Wednesday.
Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today reported business and financial results for the second quarter ended June 30, 2005, highlighted by strong revenue performance and the company's first profitable quarter.
Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has sold its raw materials and manufacturing operations in Hungary to Sun Pharmaceutical Industries Ltd. of India.
U.S. biotechnology company Velcura Therapeutics®, Inc. announced a license agreement with Nippon Chemiphar Co. (Chemiphar), Ltd., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange.